Declan Doogan, Director at Biohaven Pharmaceutical Holding Co Ltd. (BHVN), sold 75,480 shares at $117.87 ($8.8M) on 2021-11-16, disclosed to the SEC on 2021-11-17.
Open-market sale of $8.8M BHVN by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $115.90 | 12,437 | $1.4M | 16.4% |
| 2 | $115.90 | 12,437 | $1.4M | 16.4% |
| 3 | $116.69 | 18,230 | $2.1M | 24.2% |
| 4 | $116.69 | 18,230 | $2.1M | 24.2% |
| 5 | $117.87 | 7,073 | $834K | 9.5% |
| 6 | $117.87 | 7,073 |
| $834K |
| 9.5% |
| Total | $116.65 avg | 75,480 | $8.8M | 100% |
| Filing → |
| BHVN | SELL | 2022-02-11 | $5.0M | — | Filing → |
| BHVN | SELL | 2021-12-01 | $5.5M | — | Filing → |
| BHVN | SELL | 2020-06-17 | $7.3M | — | Filing → |